Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications

Pediatric Drugs

Volumn 18, Issue 1, 2016, Pages 1-11

  Tamma, Seetha M ^a   Hsu, Alice J ^b   Tamma, Pranita D ^c  

^a LONG ISLAND UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ABDOMINAL INFECTION; ANAEROBE; ANTIBIOTIC THERAPY; ARTICLE; BURKHOLDERIA CEPACIA; CHILD HEALTH CARE; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; FEVER; HEADACHE; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; MULTIDRUG RESISTANCE; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; CHILD; INTRAABDOMINAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHILD; HUMANS; INTRAABDOMINAL INFECTIONS; PENICILLANIC ACID;

EID: 84956875214     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-015-0157-x     Document Type: Article

References (50)

1. Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 × ′20 Progress–development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685–94.
2. Generating Antibiotic Incentives Now Act of 2011. https://www.congress.gov/bill/112th-congress/house-bill/2182. Accessed 28 Nov 2015.
3. Antibiotic Development to Advance Patient Treatment Act of 2013. https://www.congress.gov/bill/113th-congress/house-bill/3742. Accessed 28 Nov 2015.
4. ZERBAXA (ceftolozane/tazobactam) Current Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. Accessed 28 Nov 2015.
5. Europeans Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003772/human_med_001917.jsp&mid=WC0b01ac058001d124. Accessed 28 Nov 2015.
6. Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933–7.
7. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.
8. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane/tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56:3086–91.
9. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57:1577–82.
10. Vanscoy B, Mendes RE, McCauley J, et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with cefolozane. Antimicrob Agents Chemother. 2013;2013(57):5924–31.
11. Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane/tazobactam. Antimicrob Agents Chemother. 2014;58:2249–55.
12. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–71.
13. Pharmacokinetic and safety study of ceftolozane/tazobactam in pediatric participants receiving antibiotic therapy for proven or suspected gram-negative infection or for peri-operative prophylaxis (MK-7625A-010). https://clinicaltrials.gov/ct2/show/NCT02266706. Accessed 28 Nov 2015.
14. Reed MD, Goldfarb J, Yamashita TS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994;38:2817–26.
15. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). https://clinicaltrials.gov/ct2/show/NCT02070757. Accessed 28 Nov 2015.
16. Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67:2463–9.
17. Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2015. doi:10.1002/jcph.566. [Epub ahead of print].
18. Melchers MJ, Mavridou E, Seyedmousavi S, et al. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. AAC. 2015;59:3373–6.
19. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–5.
20. Population pharmacokinetics and safety of intravenous ceftolozane/tazobactam in adult cystic fibrosis patients. https://clinicaltrials.gov/ct2/show/NCT02421120. Accessed 28 Nov 2015.
21. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane/tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58:1218–23.
22. Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane/tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:5350–7.
23. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–64.
24. Centers for diseases control and prevention. Get smart for healthcare. http://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html. Accessed 28 Nov 2015.
25. Snydman DR, Jacobus NV, McDermott LA, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007). Clin Infect Dis. 2010;50(Suppl 1):S26–33.
26. Package insert for Zosyn (Piperacillin and tazobactam for injection, USP). http://labeling.pfizer.com/showlabeling.aspx?id=416. Accessed 28 Nov 2015.
27. Smith JM, Avdic E, Tamma PD, et al. Risk factors for resistance to β-lactam/β-lactamase inhibitors and ertapenem in Bacteroides bacteremia. Antimicrob Agents Chemother. 2015;59:5049–51.
28. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother. 2014;69:2713–22.
29. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533–9.
30. Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69:266–77.
31. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–10.
32. Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother. 2013;57:5707–9.
33. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969–76.
34. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993;37:851–8.
35. Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother. 2006;50:3179–82.
36. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001;45:3548–54.
37. Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–25.
38. Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36(8):981–5.
39. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane/tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–56.
40. Eckmann C, Solomkin J. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2015;16:271–80.
41. Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane/tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091–9.
42. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65:1972–4.
43. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51:826–30.
44. Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009;34:402–6.
45. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from US hospitals. Antimicrob Agents Chemother. 2014;58:6844–50.
46. VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane–tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother. 2013;57:4134–8.
47. Kuti JL, Pettit RS, Neu N, et al. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis. 2015;83:53–5.
48. Zamorano L, Juan C, Fernandez-Olmos A, Ge Y, Canton R, Oliver A. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010;16:1482–7.
49. Regulation (EC) No 1901/2006 of the european parliament and of the council of 12 December 2006. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 28 Nov 2015.
50. United states food and drug administration. Pediatric development of the drug or biological product. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM338453.pdf. Accessed 28 Nov 2015.